Loading...
Please wait, while we are loading the content...
Similar Documents
Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia
| Content Provider | Scilit |
|---|---|
| Author | Patel, Vivek L. Mahévas, Matthieu Lee, Soo Y. Stasi, Roberto Cunningham-Rundles, Susanna Godeau, Bertrand Kanter, Julie Neufeld, Ellis Taube, Tillmann Ramenghi, Ugo Shenoy, Shalini Ward, Mary J. Mihatov, Nino Patel, Vinay L. Bierling, Philippe Lesser, Martin Cooper, Nichola Bussel, James B. |
| Copyright Year | 2012 |
| Description | Treatments for immune thrombocytopenic purpura (ITP) providing durable platelet responses without continued dosing are limited. Whereas complete responses (CRs) to B-cell depletion in ITP usually last for 1 year in adults, partial responses (PRs) are less durable. Comparable data do not exist for children and 5-year outcomes are unavailable. Patients with ITP treated with rituximab who achieved CRs and PRs (platelets > 150 × $10^{9}$/L or 50-150 × $10^{9}$/L, respectively) were selected to be assessed for duration of their response; 72 adults whose response lasted at least 1 year and 66 children with response of any duration were included. Patients had baseline platelet counts < 30 × $10^{9}$/L; 95% had ITP of > 6 months in duration. Adults and children each had initial overall response rates of 57% and similar 5-year estimates of persisting response (21% and 26%, respectively). Children did not relapse after 2 years from initial treatment whereas adults did. Initial CR and prolonged B-cell depletion predicted sustained responses whereas prior splenectomy, age, sex, and duration of ITP did not. No novel or substantial long-term clinical toxicity was observed. In summary, 21% to 26% of adults and children with chronic ITP treated with standard-dose rituximab maintained a treatment-free response for at least 5 years without major toxicity. These results can inform clinical decision-making. |
| Related Links | https://ashpublications.org/blood/article-pdf/119/25/5989/981938/zh802512005989.pdf |
| Ending Page | 5995 |
| Page Count | 7 |
| Starting Page | 5989 |
| DOI | 10.1182/blood-2011-11-393975 |
| Journal | Blood |
| Issue Number | 25 |
| Volume Number | 119 |
| Language | English |
| Publisher | American Society of Hematology |
| Publisher Date | 2012-06-21 |
| Access Restriction | Open |
| Subject Keyword | Hematology Children Adults Treatment Decision Making Itp Sup Prs Toxicity Crs Rituximab Journal: Blood (Vol- 2010, Issue- 25) |
| Content Type | Text |
| Resource Type | Article |
